2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T6fb,Cascade genetic testing in families with hereditary cancer syndromes is an important strategy to reduce the burden of cancer, but testing of relatives is low. Direct engagement of relatives through cancer survivors is a promising approach to bridge this gap. We conducted a population-based cluster-randomized clinical trial (Genetic Information and Family Testing [GIFT]) of an online, direct-to-family, cancer genetic education and communication tool including the offer of home testing to adult relatives of cancer survivors diagnosed in 2018-2019 who carried a pathogenic variant. We selected patients through SEER and surveyed them for eligibility followed by a trial invitation. Two features were randomized: assistance from a human navigator (yes, no) and testing cost (free Four thousand three hundred patients were surveyed and 2,285 responded (53.1%); 2,006 eligible respondents were invited (87.8%) and 414 enrolled (20.6%). Enrolled patients reported a total of 4,946 first- and second-degree relatives (mean, 12.3; standard deviation [SD], 8.6); they invited 948 relatives (19.2%) and 303 enrolled (32.0%). Most enrolled relatives ordered testing (267, 91.3%); more than double were tested in the free versus $50 arm (odds ratio [OR], 2.5 [1.6-3.9]), but the baseline fraction tested was low at 0.03 and thus the absolute increase was modest (0.04 [95% CI, 0.02 to 0.05]). We did not find evidence for increased testing in the navigation arm (OR, 1.3 [0.8-2.1]). GIFT is a promising blueprint for online cascade genetic education and testing. Results suggest that a low-cost, population-level intervention could be deployed without a human navigator. Additional intervention strategies are needed to increase the modest invitation and testing uptake observed in this study.31:Ta4e, PURPOSE Cascade genetic testing in families with hereditary cancer syndromes is an important strategy to reduce the burden of cancer, but testing of relatives is low. Direct engagement of relatives through cancer survivors is a promising approach to bridge this gap. METHODS We conducted a population-based cluster-randomized clinical trial (Genetic Information and Family Testing [GIFT]) of an online, direct-to-family, cancer genetic education and communication tool including the offer of home testing to adult relatives of cancer survivors diagnosed in 2018-2019 who carried a pathogenic variant. We selected patients through SEER and surveyed them for eligibility followed by a trial invitation. Two features were randomized: assistance from a human navigator (yes, no) and testing cost (free v $50). We hypothesized that the fraction of relatives tested in a family (primary outcome) would be higher with a navigator and free testing. RESULTS Four thousand three hundred patients were surveyed and 2,285 responded (53.1%); 2,006 eligible respondents were invited (87.8%) and 414 enrolled (20.6%). Enrolled patients reported a total of 4,946 first- and second-degree relatives (mean, 12.3; standard deviation [SD], 8.6); they invited 948 relatives (19.2%) and 303 enrolled (32.0%). Most enrolled relatives ordered testing (267, 91.3%); more than double were tested in the free versus $50 arm (odds ratio [OR], 2.5 [1.6-3.9]), but the baseline fraction tested was low at 0.03 and thus the absolute increase was modest (0.04 [95% CI, 0.02 to 0.05]). We did not find evidence for increased testing in the navigation arm (OR, 1.3 [0.8-2.1]). CONCLUSION GIFT is a promising blueprint for online cascade genetic education and testing. Results suggest that a low-cost, population-level intervention could be deployed without a human navigator. Additional intervention strategies are needed to increase the modest invitation and testing uptake observed in this study. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Hereditary Cancer Syndromes: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Hereditary Cancer Syndromes (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Hereditary%20Cancer%20Syndromes\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Hereditary Cancer Syndromes\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Hereditary%20Cancer%20Syndromes\"}]}}"}}]],["$","$L2f",null,{"title":"Hereditary Cancer Syndromes: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Hereditary Cancer Syndromes with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1200/jco-25-02196","pmid":"41875376","title":"Results From the Genetic Information and Family Testing Study: A Cluster-Randomized Trial","journal_title":"Journal of Clinical Oncology","journal_issn":"0732-183X","published_at":"2026-03-24T00:00:00.000Z","url":"https://doi.org/10.1200/jco-25-02196","source_score":62,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-05-02","doi":"10.1200/jco-25-02196","days":"14","issn":"0732-183X","rank":"8","field":"Clinical Medicine","score":"62","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1200/JCO-25-02196","title":"Results From the Genetic Information and Family Testing Study: A Cluster-Randomized Trial.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","methods":"","results":"Four thousand three hundred patients were surveyed and 2,285 responded (53.1%); 2,006 eligible respondents were invited (87.8%) and 414 enrolled (20.6%). Enrolled patients reported a total of 4,946 first- and second-degree relatives (mean, 12.3; standard deviation [SD], 8.6); they invited 948 relatives (19.2%) and 303 enrolled (32.0%). Most enrolled relatives ordered testing (267, 91.3%); more than double were tested in the free versus $50 arm (odds ratio [OR], 2.5 [1.6-3.9]), but the baseline fraction tested was low at 0.03 and thus the absolute increase was modest (0.04 [95% CI, 0.02 to 0.05]). We did not find evidence for increased testing in the navigation arm (OR, 1.3 [0.8-2.1]).","abstract":"$30","keywords":[],"pubmed_id":"41875376","conclusions":"GIFT is a promising blueprint for online cascade genetic education and testing. Results suggest that a low-cost, population-level intervention could be deployed without a human navigator. Additional intervention strategies are needed to increase the modest invitation and testing uptake observed in this study.","publication_date":"2026-03-24T00:00:00"},"crossref":{"DOI":"10.1200/jco-25-02196","URL":"https://doi.org/10.1200/jco-25-02196","ISSN":["0732-183X","1527-7755"],"link":[{"URL":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-02196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1216-1224","type":"journal-article","issue":"13","score":1,"title":["Results From the Genetic Information and Family Testing Study: A Cluster-Randomized Trial"],"author":[{"given":"Steven J.","family":"Katz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI"},{"name":"Department of Health Management and Policy, School of Public Health and Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}]},{"given":"Timothy P.","family":"Hofer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}]},{"given":"Paul","family":"Abrahamse","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}]},{"given":"Rebecca R.","family":"Courser","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}]},{"given":"Rachel","family":"Hodan","sequence":"additional","affiliation":[{"name":"Cancer Genetics, Stanford Health Care, Stanford, CA"}]},{"given":"Rachel S.","family":"Tocco","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Michigan, Ann Arbor, MI"}]},{"given":"Sonia","family":"Rios-Ventura","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University, Stanford, CA"}]},{"given":"Kevin C.","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA"}]},{"given":"Ann S.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, University of Southern California, Los Angeles, CA"}]},{"given":"Melissa K.","family":"Frey","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY"}]},{"given":"Lawrence C.","family":"An","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI"}]},{"given":"Allison W.","family":"Kurian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University, Stanford, CA"},{"name":"Department of Epidemiology and Population Health, Stanford University, Stanford, CA"}]}],"issued":{"date-parts":[[2026,5,1]]},"member":"233","prefix":"10.1200","source":"Crossref","volume":"44","created":{"date-time":"2026-03-24T19:59:09Z","timestamp":1774382349000,"date-parts":[[2026,3,24]]},"indexed":{"date-time":"2026-05-01T07:54:15Z","timestamp":1777622055924,"date-parts":[[2026,5,1]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://ascopubs.org/doi/10.1200/JCO-25-02196"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-09-11"},{"name":"revised","group":{"name":"publication_history","label":"Publication History"},"label":"Revised","order":1,"value":"2026-01-09"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2026-02-18"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-03-24"}],"deposited":{"date-time":"2026-04-28T22:00:22Z","timestamp":1777413622000,"date-parts":[[2026,4,28]]},"issn-type":[{"type":"print","value":"0732-183X"},{"type":"electronic","value":"1527-7755"}],"published":{"date-parts":[[2026,5,1]]},"publisher":"American Society of Clinical Oncology (ASCO)","reference":[{"DOI":"10.1200/JCO.20.00140","key":"e_1_3_11_2_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/jnci/djy147","key":"e_1_3_11_3_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10689-016-9893-5","key":"e_1_3_11_4_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.19.02005","key":"e_1_3_11_5_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.22.02833","key":"e_1_3_11_6_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.24.00122","key":"e_1_3_11_7_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2015.63.0996","key":"e_1_3_11_8_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.19.02010","key":"e_1_3_11_9_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_11_10_2","year":null,"issue":null,"author":"Whitaker KD","volume":null,"first-page":null,"unstructured":"Whitaker KD, Obeid E, Daly MB, et al: Cascade genetic testing for hereditary cancer risk: An underutilized tool for cancer prevention. JCO Precis Oncol 10.1200/PO.21.00163","article-title":"Cascade genetic testing for hereditary cancer risk: An underutilized tool for cancer prevention","journal-title":"JCO Precis Oncol","doi-asserted-by":null},{"DOI":"10.6004/jnccn.2021.0001","key":"e_1_3_11_11_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.23.02225","key":"e_1_3_11_12_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.24.00662","key":"e_1_3_11_13_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1245/s10434-019-07549-8","key":"e_1_3_11_14_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.6004/jnccn.2017.0022","key":"e_1_3_11_15_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10689-024-00373-4","key":"e_1_3_11_16_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/OP.22.00677","key":"e_1_3_11_17_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.22.00303","key":"e_1_3_11_18_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s10689-022-00316-x","key":"e_1_3_11_19_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s12885-025-13744-6","key":"e_1_3_11_20_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_11_21_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Hofer TP Abrahamse P Katz SJ: GIFT trial open science supplement. https://intmed-cansort.github.io/gift-main/interactions.html","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"e_1_3_11_22_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Hofer TP Abrahamse P Katz SJ: GIFT trial open science supplement. https://intmed-cansort.github.io/gift-main/","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1200/JCO.2016.70.3439","key":"e_1_3_11_23_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_11_24_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Katz SJ Abrahamse P Furgal A et al: Patient engagement with clinicians and family members about genetic test results across risk groups in women with hereditary cancer susceptibility. JCO Oncol Pract 10.1200/OP-25-00776 [epub ahead of print on January 13 2026]","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,5,1]]}},"update-policy":"https://doi.org/10.1200/crossmark","alternative-id":["10.1200/JCO-25-02196"],"content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Clinical Oncology"],"published-print":{"date-parts":[[2026,5,1]]},"reference-count":23,"published-online":null,"references-count":23,"clinical-trial-number":[{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct05552664"}],"short-container-title":["J Clin Oncol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1200/jco-25-02196","is_oa":false,"title":"Results From the Genetic Information and Family Testing Study: A Cluster-Randomized Trial","updated":"2026-03-25T16:21:05+00:00","published_date":"2026-03-24","best_oa_location":null}},"created_at":"2026-05-07T22:51:18.169Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1200/jco-25-02196","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1200/jco-25-02196","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1200/jco-25-02196","tag_type":"condition","value":"Hereditary Cancer Syndromes","value_numeric":null},{"paper_doi":"10.1200/jco-25-02196","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1200/jco-25-02196","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1200/jco-25-02196","tag_type":"modality","value":"Cascade Genetic Testing","value_numeric":null},{"paper_doi":"10.1200/jco-25-02196","tag_type":"modality","value":"Genetic Counseling / Navigation","value_numeric":null},{"paper_doi":"10.1200/jco-25-02196","tag_type":"sample_size","value":"n=414 (patients enrolled); 303 relatives enrolled","value_numeric":414},{"paper_doi":"10.1200/jco-25-02196","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1200/jco-25-02196","tag_type":"study_design","value":"Cluster-Randomized Trial","value_numeric":null},{"paper_doi":"10.1200/jco-25-02196","tag_type":"warning","value":"Impact flag 'practice_changing' applied cautiously: the absolute testing increase was modest (0.04), but the finding that navigator assistance is unnecessary has direct resource-allocation implications.","value_numeric":null},{"paper_doi":"10.1200/jco-25-02196","tag_type":"warning","value":"Sample size tag reflects enrolled patients (n=414); total surveyed was 4,300 and total relatives reported was 4,946 — the trial's 'cluster' unit was the patient-family, so effective N varies by analysis level.","value_numeric":null},{"paper_doi":"10.1200/jco-25-02196","tag_type":"warning","value":"The study sourced patients via SEER (2018–2019 diagnoses); generalizability to current clinical populations or non-US settings is uncertain.","value_numeric":null}],"summaries":{"what_studied":"This cluster-randomized trial (GIFT) tested an online, direct-to-family cancer genetic education and communication tool — including home testing — for adult relatives of cancer survivors carrying a pathogenic variant. Two features were randomized: human navigator assistance (yes vs. no) and testing cost (free vs. $50).","key_result":"Of 4,946 reported relatives, only 19.2% were invited and 32% of those enrolled; 91.3% of enrolled relatives ordered testing. Free testing more than doubled the odds of testing vs. $50 (OR 2.5, 95% CI 1.6–3.9), but the absolute increase in the fraction tested was modest (0.04, 95% CI 0.02–0.05). Human navigation did not significantly improve testing uptake (OR 1.3, 95% CI 0.8–2.1).","limitations":"Only 20.6% of eligible patients enrolled, limiting generalizability. Patients invited just 19.2% of their relatives, creating a major upstream bottleneck the intervention could not overcome. The absolute baseline testing fraction was very low (0.03), so even a significant relative improvement produced a small absolute gain.","practice_takeaway":"Removing cost barriers (offering free testing) meaningfully increases cascade genetic testing uptake and can be deployed without a human navigator, reducing program complexity and cost. However, clinicians should recognize that most relatives are never invited — strategies to boost patient-to-relative outreach remain the critical gap."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Hereditary Cancer Syndromes"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Hereditary Cancer Syndromes"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Hereditary Cancer Syndromes"}}}]]

Papers